Nanjing Well Pharmaceutical Co Ltd (603351) - Total Liabilities
Based on the latest financial reports, Nanjing Well Pharmaceutical Co Ltd (603351) has total liabilities worth CN¥819.31 Million CNY (≈ $119.89 Million USD) as of September 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Also explore Nanjing Well Pharmaceutical Co Ltd (603351) net asset momentum to track the company's year-over-year net asset growth rate.
Nanjing Well Pharmaceutical Co Ltd - Total Liabilities Trend (2014–2024)
This chart illustrates how Nanjing Well Pharmaceutical Co Ltd's total liabilities have evolved over time, based on quarterly financial data. See Nanjing Well Pharmaceutical Co Ltd (603351) FCF generation index to measure how efficiently the company converts operating cash flow to free cash.
Nanjing Well Pharmaceutical Co Ltd Competitors by Total Liabilities
The table below lists competitors of Nanjing Well Pharmaceutical Co Ltd ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Anhui Gourgen Traffic Construction Co Ltd
SHG:603815
|
China | CN¥7.49 Billion |
|
iHeartMedia Inc Class A
NASDAQ:IHRT
|
USA | $6.81 Billion |
|
CMS Info Systems Limited
NSE:CMSINFO
|
India | Rs8.38 Billion |
|
Well Lead Med Co Ltd
SHG:603309
|
China | CN¥960.53 Million |
|
PostNL NV
AS:PNL
|
Netherlands | €2.02 Billion |
|
BlackRock Core Bond Closed Fund
NYSE:BHK
|
USA | $346.00 Million |
|
Yingkou Jinchen Mach Co Ltd
SHG:603396
|
China | CN¥2.43 Billion |
|
Shanxi Huhua Group Co Ltd
SHE:003002
|
China | CN¥726.24 Million |
Liability Composition Analysis (2014–2024)
This chart breaks down Nanjing Well Pharmaceutical Co Ltd's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see 603351 company net worth.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 1.29 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.47 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.32 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Nanjing Well Pharmaceutical Co Ltd's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Nanjing Well Pharmaceutical Co Ltd (2014–2024)
The table below shows the annual total liabilities of Nanjing Well Pharmaceutical Co Ltd from 2014 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-12-31 | CN¥672.72 Million ≈ $98.44 Million |
-1.97% |
| 2023-12-31 | CN¥686.22 Million ≈ $100.42 Million |
+4.65% |
| 2022-12-31 | CN¥655.76 Million ≈ $95.96 Million |
+43.80% |
| 2021-12-31 | CN¥456.01 Million ≈ $66.73 Million |
+35.41% |
| 2020-12-31 | CN¥336.75 Million ≈ $49.28 Million |
+55.15% |
| 2019-12-31 | CN¥217.06 Million ≈ $31.76 Million |
+12.12% |
| 2018-12-31 | CN¥193.59 Million ≈ $28.33 Million |
+0.45% |
| 2017-12-31 | CN¥192.73 Million ≈ $28.20 Million |
+23.35% |
| 2016-12-31 | CN¥156.25 Million ≈ $22.86 Million |
-19.05% |
| 2015-12-31 | CN¥193.01 Million ≈ $28.24 Million |
+7.86% |
| 2014-12-31 | CN¥178.94 Million ≈ $26.19 Million |
-- |
About Nanjing Well Pharmaceutical Co Ltd
Nanjing Well Pharmaceutical Group Co.,Ltd. focuses on the research and development, production, and sale of pharmaceutical excipients and synthetic lubricating base oils to the pharmaceutical companies in China. It is involved in the bio-based material manufacturing, sales, and technology development; technical development and consulting; bio-based material technology research and development; bi… Read more